Abstract 5568
Background
Sarcoma patients, like many other patients with rare diseases, often experience a long diagnostic trajectory, which may negatively affect their outcome in many ways. So far, research on diagnostic intervals has been retrospective. Prospective studies with large patient numbers comparing diagnostic intervals in different health care systems have not been performed. Moreover, next to survival, health-related quality of life (HRQoL) and patient satisfaction can be affected by experiencing diagnostic delay. Currently, no data are available on how the diagnostic trajectory impacts patient-reported outcomes among sarcoma patients.
Trial design
A longitudinal cohort study, QUEST, will be conducted among newly diagnosed sarcoma patients 18 years and older in one of the participating study centers in The Netherlands (five centers) or United Kingdom (3 centers). Patients will be invited before start of treatment and asked to complete questionnaires on the diagnostic pathway, risk factors (demographic, geographic, tumour characteristics etc) and patient-reported outcomes (HRQoL, social functioning, psychological distress, care satisfaction) at diagnosis and 3, 6, 12 and 24 months later. Data collection will be done within PROFILES, an established international registry for cancer patient reported outcomes. Clinical data, including vital status and tumour characteristics, will be collected from patients’ records. We aim to include 530 patients within two years, recruitment started 01-02-2018, and up till now 300patients completed baseline questionnaires (219 in NL, response rate 60%; 66 in UK, response rate 45%). Descriptive statistics will be used to quantify diagnostic intervals. The association between diagnostic interval and HRQoL, stage at diagnosis, primary treatment and survival will be explored.
Clinical trial identification
Protocol Record 2017-3881.
Editorial acknowledgement
Legal entity responsible for the study
Winette van der Graaf.
Funding
Radboudumc PROFILES registry.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract